Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs CIPROFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair.
400 mg intravenously every 8-12 hours over 60 minutes.
400 mg IV every 12 hours or 500 mg orally every 12 hours for uncomplicated infections; 400 mg IV every 8 hours or 750 mg orally every 12 hours for severe/complicated infections.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
4 hours (3-5 hours) in normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 20-50 mL/min) and 12-24 hours in severe impairment (CrCl <20 mL/min)
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); fecal (15-25% via biliary and transintestinal elimination); <1% as metabolites
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic